Karyopharm Therapeutics (KPTI) Cash & Current Investments (2012 - 2026)

Karyopharm Therapeutics (KPTI) has 14 years of Cash & Current Investments data on file, last reported at $50.9 million in Q4 2025.

• Quarterly Cash & Current Investments fell 64.76% year-over-year to $50.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $50.9 million (down 64.76% YoY) and the FY2025 annual result came in at $50.9 million, down 64.76% from the prior year.
• Cash & Current Investments rose to $50.9 million in Q4 2025, from $43.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $278.0 million in Q4 2022 to a low of $43.5 million in Q3 2025.
• A 5-year average of $139.0 million and a median of $146.5 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments sank 82.14% — and 2022, when it soared 524.57%.
• Tracing KPTI's Cash & Current Investments over 5 years: stood at $44.5 million in 2021, then soared by 524.57% to $278.0 million in 2022, then slumped by 31.13% to $191.4 million in 2023, then fell by 24.5% to $144.5 million in 2024, then plunged by 64.76% to $50.9 million in 2025.
• The last three Cash & Current Investments figures came in at $50.9 million (Q4 2025), $43.5 million (Q3 2025), and $47.9 million (Q2 2025), per Business Quant data.